Full-Time
Updated on 9/4/2026
Licenses GPCR discovery platform to pharma
$200k - $220k/yr
South San Francisco, CA, USA
In Person
Travel domestically and internationally up to 20% of the time.
Bachelor's, Master's, PhD
See people who can refer or advise you
Septerna develops and licenses a platform called Native Complex™ that enables drug discovery on G protein-coupled receptors (GPCRs) outside of cells. The platform reproduces GPCRs with their original structure, function, and dynamics, allowing scientists to design drugs based on GPCR structures and to perform ultra-large-scale screening across the full GPCR target class. This helps unlock GPCR targets that were previously hard to study and could lead to new medicines. The company differentiates itself by offering an industrial-scale, structure-based discovery workflow specifically for GPCRs, paired with a licensing business model for pharmaceutical companies. Its goal is to expand therapeutic options by turning more GPCRs—previously considered undruggable—into viable drug targets and to bring GPCR-targeted medicines to market through licensing and partnerships.
Company Size
51-200
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2022
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Stock Options
Septerna, a clinical-stage biotechnology company focused on G protein-coupled receptor drug discovery, has appointed Rajiv Patni as chief medical officer. Dr Patni brings over 25 years of experience in biopharmaceutical research, development, and regulatory affairs. Dr Patni previously served as chief executive officer at Judo Bio and held senior positions at several companies including Reata Pharmaceuticals, Global Blood Therapeutics, and Portola Pharmaceuticals. He has contributed to programmes resulting in 10 regulatory approvals or label expansions across the US, Europe, and other markets. The appointment comes as Septerna advances its pipeline targeting endocrinology, immunology, and other therapeutic areas. The company's proprietary Native Complex Platform is designed to enable new approaches to developing oral small molecule drug candidates.
Septerna appoints industry veteran Rajiv Patni, M.D., as Chief Medical Officer. August 25, 2026 08:00 ET | Source: Septerna, Inc. SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) - Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations. "We are thrilled to welcome Rajiv to the team as we execute on our strategy to develop differentiated oral medicines targeting GPCRs," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "Rajiv brings deep clinical development experience across multiple therapeutic areas and a successful track record of guiding investigational medicines from early clinical studies through regulatory agency approvals. His leadership will be instrumental as we advance our clinical programs and continue to build a world-class development organization to deliver new medicines for patients in need." "Throughout my career I have joined companies at inflection points in their R&D trajectory, and that is where Septerna is today," said Dr. Patni. "Our pipeline targets significant unmet needs spanning endocrinology, immunology, and other therapeutic areas. I look forward to helping translate Septerna's unique expertise in GPCR drug discovery into clinical evidence and ultimately into important new medicines for patients who need better oral treatment options." Dr. Patni joins Septerna from Judo Bio where he most recently served as Chief Executive Officer. Previously, he was Chief Research and Development Officer at Reata Pharmaceuticals. Earlier, Dr. Patni served as Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals and Actelion Pharmaceuticals, companies that, together with Reata, were subsequently acquired. Earlier in his career, Dr. Patni led development teams at Pfizer and Roche Pharmaceuticals. Over the course of his career, Dr. Patni has contributed to programs that resulted in 10 regulatory agency approvals or label expansions in the United States, Europe and additional markets. He currently serves as a director of BioXcel Therapeutics. Dr. Patni holds an M.D. from the Icahn School of Medicine at Mt. Sinai and completed his internal medicine residency and cardiology fellowship at the Albert Einstein College of Medicine. About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company's proprietary Native Complex Platform(R) is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Septerna (NASDAQ: SEPN) grows Q1 revenue to $26.5M, trims loss. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Septerna reported strong top-line growth for the three months ended March 31, 2026, with revenue of $26.5 million driven by its Novo Nordisk collaboration, compared with $0.2 million a year earlier. Revenue included recognition of upfront, research and milestone consideration under the agreement. Research and development expense rose to $29.5 million and general and administrative expense to $10.3 million, reflecting pipeline expansion and public-company costs. Net loss narrowed to $8.6 million from $21.5 million, helped by collaboration revenue and $5.0 million of interest income. Septerna ended the quarter with $522.1 million in cash, cash equivalents and marketable securities and deferred revenue of $152.0 million, and expects this liquidity to fund operations at least into 2029. The company also initiated a Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with data anticipated in late 2026 or early 2027. Key figures. Revenue: $26,523 thousand Net loss: $8,637 thousand R&D expense: $29,535 thousand +5 more Key terms. Native Complex Platform(R), G protein-coupled receptor, at-the-market offering, deferred revenue, +2 more Earnings snapshot. Revenue: $26,523 thousand 05/11/2026 - 01:08 PM Faq. How much revenue did Septerna (SEPN) report for Q1 2026? Septerna reported Q1 2026 revenue of $26.5 million, up from $0.2 million in Q1 2025. This increase primarily reflects recognition of upfront, research and milestone consideration from its Novo Nordisk collaboration under long-term licensing and research agreements. What was Septerna's net loss for the three months ended March 31, 2026? Septerna recorded a Q1 2026 net loss of $8.6 million, narrowing from $21.5 million a year earlier. Higher collaboration revenue and $5.0 million of interest income offset increased research and development and general and administrative expenses tied to pipeline growth. What is Septerna's cash and investment position as of March 31, 2026? As of March 31, 2026, Septerna held $522.1 million in cash, cash equivalents and marketable securities. Management believes this balance will fund planned operating and capital needs at least into 2029, supporting ongoing research, clinical development and public-company obligations. How significant is Septerna's Novo Nordisk collaboration to its Q1 2026 results? The Novo Nordisk collaboration was central to Q1 2026 results, contributing $26.5 million of revenue. This included recognition of a portion of the $195.0 million upfront payment, research services and milestones, with $219.1 million of transaction price still unrecognized for future periods. What clinical progress did Septerna (SEPN) report for SEP-479? Septerna announced first dosing in a Phase 1 trial of SEP-479, its oral PTH1R agonist for hypoparathyroidism. The randomized single- and multiple-ascending dose study in up to 150 healthy adults assesses safety, tolerability, pharmacokinetics and pharmacodynamics, with initial data expected late 2026 or early 2027. How are Septerna's research and development expenses trending? Research and development expenses rose to $29.5 million in Q1 2026 from $19.3 million in Q1 2025. The increase reflects higher employee-related costs, external program spending across the pipeline, and platform investments as the company advances multiple GPCR-targeted oral small molecule programs.
Septerna (nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Septerna, Inc. has begun a Phase 1 clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism. The randomized, placebo-controlled study in healthy adults includes single-ascending and multiple-ascending dose cohorts, with enrollment of up to approximately 150 participants in Australia. The trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics, including effects on endogenous parathyroid hormone and serum calcium, and includes a crossover food-effect study. Septerna anticipates reporting SAD/MAD data in late 2026 or early 2027. SEP-479 aims to offer once-daily oral PTH replacement based on supportive preclinical data. Insights. Septerna advances SEP-479 into Phase 1, adding a new clinical catalyst while keeping risk at an early stage. Septerna has dosed first participants in a Phase 1 study of SEP-479, an oral PTH1R agonist for hypoparathyroidism, with up to 150 healthy volunteers in single- and multiple-ascending dose cohorts plus a food-effect arm. This moves the asset from preclinical into human testing. The company highlights robust preclinical data, including normalization of serum calcium in animal models and a safety profile where hypercalcemia was the main dose-limiting effect. However, all efficacy and tolerability expectations in patients remain unproven until later-stage trials, and Phase 1 outcomes can diverge from preclinical findings. Management guides to SAD/MAD readouts in late 2026 or early 2027, creating a medium-term data catalyst. Alongside this, the broader pipeline and the Novo Nordisk collaboration, which included a $195M upfront payment and potential future milestones, underscore a multi-asset strategy that may help diversify single-program risk. 8-K event classification. 2 items: 7.01, 9.01 Key figures. Planned Phase 1 enrollment: up to ~150 subjects SEP-479 data timing: late 2026 or early 2027 Novo Nordisk upfront payment: $195M +5 more Key terms. Phase 1 clinical trial, single-ascending dose (SAD), multiple-ascending dose (MAD), hypoparathyroidism, +2 more 04/13/2026 - 08:30 AM Faq. What did Septerna (SEPN) announce about SEP-479 in this 8-K? Septerna announced dosing of the first participants in a Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist for hypoparathyroidism. The study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult volunteers using single- and multiple-ascending dose designs. When does Septerna (SEPN) expect Phase 1 data for SEP-479? Septerna anticipates Phase 1 SAD/MAD clinical data for SEP-479 in late 2026 or early 2027. The trial assesses safety, tolerability, and biomarker responses, including serum calcium and endogenous parathyroid hormone, to guide potential dosing strategies for future hypoparathyroidism patient studies. How is Septerna's SEP-479 Phase 1 trial designed? The Phase 1 trial is randomized, placebo-controlled, and includes single-ascending dose and multiple-ascending dose cohorts in healthy adults, plus a crossover food-effect study. Up to about 150 subjects in Australia will be evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics, including calcium-related biomarkers. What unmet need is Septerna (SEPN) targeting with SEP-479? SEP-479 targets hypoparathyroidism, a disease marked by low parathyroid hormone and low blood calcium, causing cramps, fatigue, cognitive issues, and serious complications. Current care relies on frequent calcium and vitamin D dosing or daily PTH injections, leaving demand for more convenient PTH-replacement options. What other key programs does Septerna (SEPN) highlight in its presentation? Septerna highlights SEP-631, an oral MRGPRX2 negative allosteric modulator advancing toward a planned Phase 2b chronic spontaneous urticaria study in the second half of 2026, a TSHR program for Graves' disease and thyroid eye disease, and multiple metabolic programs in collaboration with Novo Nordisk targeting obesity and cardiometabolic diseases. How is Septerna (SEPN) funded for its pipeline plans? Septerna states it is well-capitalized, with cash runway expected to support operating plans at least into 2029. The company also received a $195M upfront payment from Novo Nordisk in July 2025 and is eligible for up to about $500M in potential milestones per collaboration program. Filing exhibits & attachments. 5 documents Press releases.
Septerna, a clinical-stage biotechnology company focused on G protein-coupled receptor drug discovery, has reported positive Phase 1 results for SEP-631, its oral small molecule for mast cell diseases, and announced plans to initiate a Phase 2b trial in chronic spontaneous urticaria in the second half of 2026. The company's SEP-631 demonstrated favourable safety, convenient once-daily dosing and robust suppression of wheal formation in healthy volunteers. Septerna is also advancing SEP-479 towards Phase 1 initiation in the first half of 2026 for hypoparathyroidism. Cash, cash equivalents and marketable securities totalled $548.7 million as of 31 December 2025. The company expects its cash runway to support operations at least into 2029. Full-year 2025 revenue reached $46.0 million, compared to $1.1 million in 2024, driven by collaboration payments from Novo Nordisk.